Boehringer Ingelheim· @Boehringer · X·· 2025-10-30AI 评分42
AI 导读
#NEWS：我们从 @KyowaKirin_JP 收购了一个项目，用于开发靶向自身免疫性疾病的小分子药物。我们的目标是解决这些疾病的根本原因，并提供持久疗法。 了解更多：https://go.boehringer.com/MPRF #Innovation #AutoimmuneDiseases
正文
#NEWS: We’ve acquired a program from @KyowaKirin_JP to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies.
Learn more: https://go.boehringer.com/MPRF
#Innovation #AutoimmuneDiseases
来源：Boehringer Ingelheim · x.com